3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
17
Breast Neoplasms
10
Carcinoma, Non-Small-Cell Lung
9
Neoplasm Metastasis
6
Prostatic Neoplasms
5
Melanoma
5
Lung Neoplasms
5
Solid Tumor
3
Pain, Postoperative
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Leukemia, Myeloid, Acute
3
Gastrointestinal Stromal Tumors
3
Colorectal Neoplasms
3
Anxiety Disorders
3
Recurrence
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pancreatic Neoplasms
2
Pain
2
Glioma
2
Colonic Neoplasms
2
Choledocholithiasis
2
Choledochal Cyst
2
Carcinoma
2
Advanced Solid Tumor
2
Advanced Malignancies
2
cMET-dysregulated Advanced Solid Tumors
1
Urothelial Cancer
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Interventions
Carboplatin
69
Paclitaxel
47
Radiotherapy
44
Pemetrexed
42
Cisplatin
41
Bevacizumab
36
Gemcitabine
27
Docetaxel
27
Erlotinib Hydrochloride
23
Gefitinib
18
pembrolizumab
14
Taxes
13
Vinorelbine
10
Cetuximab
10
Radiation
8
Nivolumab
8
Magnetic Resonance Spectroscopy
8
Radiosurgery
7
Platinum
7
Etoposide
7
Surgical Procedures, Operative
6
Radiotherapy, Conformal
6
ceritinib
5
capmatinib
5
aflutinib
5
Specimen Handling
5
Neoadjuvant Therapy
5
Mastectomy, Segmental
5
Cyclophosphamide
5
tislelizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma of Lung
×
Midazolam
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled